The Therapeutic Application of Atypical Antipsychotics for Treatment-Resistant Obsessive Compulsive Disorder.
- Author:
Sang Wook KIM
1
;
Bum Hee YU
Author Information
1. Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. chris12@samsung.co.kr
- Publication Type:Review
- Keywords:
Obsessive-compulsive disorder;
Atypical antipsychotics;
Serotonin reuptake inhibitors
- MeSH:
Antipsychotic Agents*;
Humans;
Obsessive-Compulsive Disorder*;
Risperidone;
Schizotypal Personality Disorder;
Serotonin Uptake Inhibitors;
Tic Disorders
- From:Korean Journal of Psychopharmacology
2001;12(2):99-105
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Although serotonin reuptake inhibitors (SRIs) are the primary therapeutic drugs for obsessive compulsive disorder (OCD), as many as 40% (up to 60%) of OCD patients do not show an adequate response to these drugs. SRI-refractory patients with OCD may have abnormalities in their central dopaminergic system as well as serotonergic system. The combination therapy with SRIs and antipsychotic drugs is considered to be effective especially for treatment-refractory OCD patients who have comorbid tic disorders or schizotypal personality disorder. Recently, the augmentation of atypical antipsychotics has been suggested to be effective in treating SRI-refractory OCD patients, and risperidone and olanzapine could be promising drugs for SRI-refractory OCD patients. We reviewed recent literatures regarding the clinical efficacy of atypical antipsychotics for treatment-refractory OCD patients.
